Asston Pharmaceu

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0SJX01015
  • NSEID:
  • BSEID: 544445
INR
78.00
-0.8 (-1.02%)
BSENSE

Apr 02

BSE+NSE Vol: 1000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

78.0078.00

52 Week

75.21126.00
Valuation
Technical
Day's Volume

CASH

1.0 k (-91.23%) Volume

Shareholding (Sep 2025)

FII

6.04%

Held by 4 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

50.66%

When is the next results date for Asston Pharmaceu?

12-Nov-2025

Asston Pharmaceu is scheduled to announce its results on 14 November 2025.

Asston Pharmaceu is scheduled to declare its results on 14 November 2025.

Read More

How has been the historical performance of Asston Pharmaceu?

15-Nov-2025

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.

Read More

Is Asston Pharmaceu overvalued or undervalued?

27-Nov-2025

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

Read More

Which are the latest news on Asston Pharmaceu?

03-Dec-2025
Is Asston Pharmaceu overvalued or undervalued?
Is Asston Pharmaceu overvalued or undervalued?

Why is Asston Pharmaceu falling/rising?

04-Dec-2025

As of 03-Dec, Asston Pharmaceuticals Ltd's stock price is declining, currently at 98.97, down 5.4% and underperforming its sector. Despite increased investor participation, the stock's volatility and significant intraday lows indicate negative sentiment.

As of 03-Dec, Asston Pharmaceuticals Ltd's stock price is falling, currently at 98.97, which reflects a decrease of 5.65 or 5.4%. This decline is notable as the stock has underperformed its sector by 5.39% today. The stock has also experienced a trend reversal, falling after two consecutive days of gains. Additionally, it touched an intraday low of Rs 92.99, marking a significant drop of 11.12%. <BR><BR>The stock has shown high volatility today, with an intraday volatility of 6.06%, indicating fluctuations in price. Despite trading above its moving averages over various periods, the current performance suggests a negative sentiment among investors. The weighted average price indicates that more volume was traded closer to the low price, further supporting the downward trend. <BR><BR>While there has been a rise in investor participation, with delivery volume increasing by 213.95% against the 5-day average, this has not translated into a positive price movement today. Overall, the combination of underperformance against the sector, significant intraday lows, and high volatility contributes to the current decline in Asston Pharmaceuticals Ltd's stock price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 67 Cr (Micro Cap)

stock-summary
P/E

17.00

stock-summary
Industry P/E

31

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

9.97%

stock-summary
Price to Book

1.74

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.81%
0%
-7.81%
6 Months
-23.53%
0%
-23.53%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Asston Pharmaceu for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary

Announcement under Regulation 30 (LODR)-Meeting Updates

30-Mar-2026 | Source : BSE

Meeting Update

Announcement under Regulation 30 (LODR)-Change in Management

30-Mar-2026 | Source : BSE

Details about the change in management.

Board Meeting Outcome for Outcome Of The Board Meeting Schedule To Be Held On 30Th March 2026

30-Mar-2026 | Source : BSE

Outcome of the Board Meeting Schedule to be held on 30th March 2026

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
60.60%
EBIT Growth (5y)
143.20%
EBIT to Interest (avg)
3.95
Debt to EBITDA (avg)
0.73
Net Debt to Equity (avg)
0.64
Sales to Capital Employed (avg)
0.59
Tax Ratio
23.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.04%
ROCE (avg)
12.72%
ROE (avg)
29.08%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
31
Price to Book Value
1.72
EV to EBIT
13.00
EV to EBITDA
12.91
EV to Capital Employed
1.65
EV to Sales
2.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.72%
ROE (Latest)
9.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
Bollinger Bands
Mildly Bearish
KST
Dow Theory
Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 4 FIIs (6.04%)

Promoter with highest holding

Ashish Narayan Sakalkar (21.77%)

Highest Public shareholder

Mahesh Vishnupant Mulay (2.88%)

Individual Investors Holdings

37.06%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Asston Pharmaceu"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 70.01% vs -43.21% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -98.46% vs 2.63% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.42",
          "val2": "9.07",
          "chgp": "70.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.24",
          "val2": "3.17",
          "chgp": "-29.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.28",
          "val2": "0.53",
          "chgp": "-47.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.35",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.03",
          "val2": "1.95",
          "chgp": "-98.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.53%",
          "val2": "34.95%",
          "chgp": "-20.42%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Asston Pharmaceu"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.04",
          "val2": "15.59",
          "chgp": "60.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.44",
          "val2": "2.55",
          "chgp": "113.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.95",
          "val2": "0.93",
          "chgp": "2.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "3.85",
          "val2": "1.36",
          "chgp": "183.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.73%",
          "val2": "16.36%",
          "chgp": "5.37%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Mar'25
Change(%)
Net Sales
15.42
9.07
70.01%
Operating Profit (PBDIT) excl Other Income
2.24
3.17
-29.34%
Interest
0.28
0.53
-47.17%
Exceptional Items
-3.35
0.00
Standalone Net Profit
0.03
1.95
-98.46%
Operating Profit Margin (Excl OI)
14.53%
34.95%
-20.42%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 70.01% vs -43.21% in Mar 2025

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -98.46% vs 2.63% in Mar 2025

All Half Yearly Resultsstock-summary
Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
25.04
15.59
60.62%
Operating Profit (PBDIT) excl Other Income
5.44
2.55
113.33%
Interest
0.95
0.93
2.15%
Exceptional Items
0.00
0.00
Standalone Net Profit
3.85
1.36
183.09%
Operating Profit Margin (Excl OI)
21.73%
16.36%
5.37%
Values in Rs Cr.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About Asston Pharmaceuticals Ltd stock-summary
stock-summary
Asston Pharmaceuticals Ltd
Micro Cap
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."